Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and Development Authority ...

Each microprojection is ‘printed’ with a small dose of vaccine in a dried formulation. When applied to the skin, the patch delivers the vaccine to the abundant immune cells that naturally ...

The US$2 million (A$3.2 million) prize will help to accelerate the use of Vaxxas' high-density microarray patch (HD-MAP) technology to administer mRNA vaccines manufactured at UQ's BASE facility.

PopVax is developing this vaccine in partnership with Germany’s LTS Lohmann Therapie-Systeme AG (LTS), a leading player in transdermal drug delivery. The Patch Forward Prize is a multi-stage $50 ...

This project adds one of the most advanced vaccine patch developers to the CEPI portfolio, as well as CastleVax’s new rapid response platform.” A commitment to equitable access CEPI and Micron ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

The award highlights BioNet's novel mRNA influenza vaccine candidate and its unparalleled manufacturing agility—critical for addressing emerging global health threats. The $50 million Patch Forward ...

The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...